Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of …

WC Meijers, A Bayes‐Genis, A Mebazaa… - European journal of …, 2021 - Wiley Online Library
New biomarkers are being evaluated for their ability to advance the management of patients
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …

Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of …

WC Meijers, A Bayes‐Genis, A Mebazaa… - European Journal of …, 2021 - eprints.gla.ac.uk
New biomarkers are being evaluated for their ability to advance the management of patients
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …

[HTML][HTML] Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European …

WC Meijers, A Bayes‐Genis, A Mebazaa… - European Journal of …, 2021 - ncbi.nlm.nih.gov
New biomarkers are being evaluated for their ability to advance the management of patients
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …

Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of …

WC Meijers, A Bayes-Genis, A Mebazaa, J Bauersachs… - 2021 - scholarbank.nus.edu.sg
New biomarkers are being evaluated for their ability to advance the management of patients
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …

Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (), European Society of …

WC Meijers - 2021 - ddd.uab.cat
New biomarkers are being evaluated for their ability to advance the management of patients
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …

Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of …

WC Meijers, A Bayes-Genis, A Mebazaa… - European Journal of …, 2021 - research.rug.nl
New biomarkers are being evaluated for their ability to advance the management of patients
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …

Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of …

WC Meijers, A Bayes-Genis, A Mebazaa… - European Journal of …, 2021 - europepmc.org
New biomarkers are being evaluated for their ability to advance the management of patients
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …

[PDF][PDF] Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European …

WC Meijers, A Bayes-Genis, A Mebazaa… - European Journal of …, 2021 - scholar.archive.org
Physicians routinely use biomarkers for the diagnosis, prognosis and management of
patients with heart failure (HF). Established biomarkers such as N-terminal pro-B-type …

Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of …

WC Meijers, A Bayes-Genis… - … journal of heart …, 2021 - pubmed.ncbi.nlm.nih.gov
New biomarkers are being evaluated for their ability to advance the management of patients
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …

Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of …

WC Meijers, A Bayes-Genis, A Mebazaa… - European Journal of …, 2021 - edoc.unibas.ch
New biomarkers are being evaluated for their ability to advance the management of patients
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …